OncoMatch/Clinical Trials/NCT05112991
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
Is NCT05112991 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Envafolimab+Lenvatinib and Envafolimab for advanced endometrial cancer.
Treatment: Envafolimab+Lenvatinib · Envafolimab — This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to evaluate objective response rate of envafolimab alone or with lenvatinib.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Endometrial Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy — first-line
Failure or intolerance of standard first-line platinum-based chemotherapy regimen for EC
Cannot have received: anti-PD-1 therapy
Has received prior treatment with any anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Cannot have received: VEGF-directed angiogenesis inhibitor
Has received prior treatment with any treatment targeting VEGF-directed angiogenesis
Lab requirements
Blood counts
Sufficient organ and bone marrow function (no hematopoietic growth factor, blood transfusion or platelet therapy was given within 14 days before the first study drug treatment)
Kidney function
Sufficient organ and bone marrow function (no hematopoietic growth factor, blood transfusion or platelet therapy was given within 14 days before the first study drug treatment)
Liver function
Sufficient organ and bone marrow function (no hematopoietic growth factor, blood transfusion or platelet therapy was given within 14 days before the first study drug treatment)
Sufficient organ and bone marrow function (no hematopoietic growth factor, blood transfusion or platelet therapy was given within 14 days before the first study drug treatment)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05112991 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy, VEGF-directed angiogenesis inhibitor disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages